Intrahepatic Cholangiocarcinoma with High Microsatellite Instability and Tumor Mutation Burden That Responded Significantly to Pembrolizumab but Perforated within a Short Period

Cholangiocarcinoma has a poor prognosis, and resection is the only curative treatment. Pembrolizumab, a programmed death receptor 1 inhibitor, has proven effective against unresectable or metastatic solid tumors with high microsatellite instability (MSI-H) or a high tumor mutation burden (TMB-H). In...

Full description

Saved in:
Bibliographic Details
Published inInternal Medicine Vol. 63; no. 8; pp. 1105 - 1112
Main Authors Yamazaki, Shiori, Kubota, Koji, Shimizu, Akira, Notake, Tsuyoshi, Umemura, Kentaro, Kamachi, Atsushi, Goto, Takamune, Tomida, Hidenori, Yamashita, Naho, Sato, Midori, Kanno, Hiroyuki, Soejima, Yuji
Format Journal Article
LanguageEnglish
Published Japan The Japanese Society of Internal Medicine 15.04.2024
Japan Science and Technology Agency
Subjects
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological - therapeutic use
Autopsy
Bile Duct Neoplasms - drug therapy
Bile Duct Neoplasms - genetics
Bile Duct Neoplasms - surgery
Bile Ducts, Intrahepatic
Biomarkers, Tumor - genetics
Chemotherapy
Cholangiocarcinoma
Cholangiocarcinoma - drug therapy
Cholangiocarcinoma - genetics
Cholangiocarcinoma - surgery
Humans
Metastases
Microsatellite Instability
microsatellite instability-high
Mutation
Pembrolizumab
Solid tumors
tumor mutation burden-high
unresectable cholangiocarcinoma
pembrolizumab
unresectable cholangiocarcinoma
microsatellite instability-high
tumor mutation burden-high
Online AccessGet full text

Cover

More Information
Summary:Cholangiocarcinoma has a poor prognosis, and resection is the only curative treatment. Pembrolizumab, a programmed death receptor 1 inhibitor, has proven effective against unresectable or metastatic solid tumors with high microsatellite instability (MSI-H) or a high tumor mutation burden (TMB-H). In the present case, pembrolizumab treatment was initiated after standard chemotherapy for MSI-H and TMB-H unresectable intrahepatic cholangiocarcinoma. Intrahepatic tumor necrosis perforated the abdominal cavity. Emergency surgery was performed, but the patient died 36 days after admission. A pathological autopsy revealed that the intrahepatic tumor had almost completely disappeared.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.1492-22